Viridian Shares Plunge 40% After REVEAL-1 Shows Statistically Significant Results for Elegrobart
Viridian Therapeutics reported that its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease met its primary endpoint with highly statistically significant results, including notable proptosis responder rates and diplopia resolution. Despite the clinical success, the company’s stock fell about 40% on the day. The study enrolled 132 pa…